Default
Allergy and immunology
Anaesthesia
Basic research
Cardiovascular medicine
Complementary medicine and alternative therapies
Critical care / intensive care
Dentistry / oral medicine
Dermatology
Emergency medicine
Endocrinology
Epidemiology
Ethics
Evidence-based medicine
Gastroenterology
Genetics
Geriatric medicine / aging
Haematology / blood transfusion
Health economics
Health policy
History of medicine
Infectious diseases
Internal medicine
Laboratory medicine
Legal and forensic medicine
Medical education
Medical informatics
Neurology
Nursing
Nutrition and metabolism
Obstetrics and gynaecology
Occupational and environmental medicine
Oncology
Ophthalmology
Organisation of health care
Otolaryngology / head and neck surgery
Paediatrics
Palliative care
Pathology
Patient-physician relationship
Pharmacology and therapeutics
Primary care, family medicine
Psychiatry and psychotherapy
Psychosomatics
Public health
Quality of care
Radiology
Rehabilitation medicine
Renal medicine
Respiratory medicine
Rheumatology
Sexual medicine
Sports medicine
Statistics and research methods
Surgery
Transplantation
Travel medicine
Urology
Two-dimensional transthoracic echocardiography at rest for the diagnosis, screening and management of pulmonary hypertension
This article reviews the current knowledge about methodologic aspects of assessing pulmonary pressure and pulmonary hypertension origin by echo, including a discussion about abnormal thresholds. It also details advanced techniques like right ventricular strain imaging and new concepts like right ventricle – pulmonary artery coupling evaluation that have become “matured” enough to be definitely brought to routine evaluation.
The importance of 18F-FDG cardiac PET/CT for the assessment of myocardial viability in ischaemic heart disease
18F-FDG cardiac PET/CT is expected to streamline resource allocation in view of the possibility to avoid costly, invasive procedures and to reduce the rate of future severe complications in coronary artery disease patients, thus further reducing the costs for advanced therapies.
Coronary and structural heart interventions in Switzerland 2019
Since 1987 the Swiss Working Group Interventional Cardiology of the Swiss Society of Cardiology coordinates the assessment of invasive diagnostic and therapeutic heart interventions across Switzerland. In 2019, 37 centres performed a total of 57,975 coronary angiographies. In 48.2% of these cases a subsequent percutaneous coronary intervention was performed. Among a broad spectrum of structural heart interventions, we have observed a constant growth of transcatheter aortic valve implantations, and a total of 1912 transcatheter aortic valve implantations were performed in 2019.
Cost-effectiveness analysis of statins in primary care: results from the Arteris cohort study
The Swiss Federal Office of Public Health performed a health technology assessment regarding statins in primary care. The chosen models may lead to a situation where a clinically indicated statin therapy is estimated not to be cost effective.
Contemporary early results of late repair of tetralogy of Fallot in children: a single-centre case series
Compared with the existing literature on complete late repair of tetralogy of Fallot in children, this study showed good early results with no mortality, similar rates of reintervention and valve-preserving surgery, higher ICU and hospital length of stay, higher incidence of significant residual right ventricular outflow tract stenosis, and lower incidence of significant pulmonary insufficiency. Repair with a transannular patch was a risk factor for significant residual right ventricular outflow tract stenosis and significant pulmonary insufficiency.
The SilenT AtRial FIBrillation (STAR-FIB) study programme – design and rationale
Anticoagulation of patients with screen-detected atrial fibrillation may prevent ischaemic strokes. The STAR-FIB study programme aims to determine the age- and sex-specific prevalence of silent atrial fibrillation and to develop a clinical prediction model to identify patients at risk of undiagnosed atrial fibrillation in a hospitalised patient population.
COVID-19 and cardiovascular disease: what have we learned?
As of 10 December, 82,127 citations were found in PubMed on COVID-19 and 5285 when “COVID-19 and cardiovascular disease” were used as search words. Many cardiovascular societies have also released statements regarding COVID-19. What have we learned from this incredible scientific excitement?
Impact of the COVID-19 pandemic on acute coronary syndromes
Prolonged delays from symptom onset to first medical contact and a decline in overall ACS incidence were observed during the first wave of the COVID-19 pandemic, with a higher threshold to call for help among ACS patients.
Cardiovascular aspects of COVID-19
In this review, findings and debates relating to the diverse aspects of cardiovascular involvement of COVID-19 are summarised and put into perspective. The authors review evidence for the role of the renin-angiotensin-aldosterone system (RAAS), the risk of pre-existing cardiovascular disease in COVID-19 susceptibility and course, and the mechanism of acute and long-term myocardial injury.
The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity
The authors explain mechanisms by which inhibitors of the renin-angiotensin-aldosterone system may increase susceptibility to and the development of cytokine storm during SARS-CoV-2 infection.
